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Abstract. The present study investigated the expression 
profile and the function of RP11-169D4.1 and explored its 
potential mechanisms in laryngeal squamous cell carcinoma. 
The biological function of RP11-169D4.1 was examined using 
the MTT assay, flow cytometric analysis, wound healing and 
Transwell assays. The relationship between RP11-169D4.1 and 
miR-205-5p was discovered by Argonaute 2 protein immu-
noprecipitation. The target gene of RP11-169D4.1 was CDH1 
which was assessed by Pearson's correlation analysis, RT-PCR 
and western blot assay. We demonstrated that RP11-169D4.1 
expression was markedly decreased in LSCC tissues and 
cell lines. The overexpression of RP11-169D4.1 inhibited the 
proliferation, migration and invasion of LSCC cell lines as well 
as promoted apoptosis. We further verified that miR-205-5p 
had binding sites with RP11-169D4.1 and that RP11-169D4.1 
could regulate the expression of CDH1. Ectopic transfection of 
RP11-169D4.1 led to a significant reduction in the downstream 
signaling molecule AKT in LSCC cells. The long non-coding 
RNA RP11-169D4.1 may serve as a tumor suppressor and a 
promising therapeutic target in laryngeal cancer, which could 
inhibit the process of EMT by regulating CDH1.
Introduction
Laryngeal carcinoma has been reported as the second most 
common head and neck squamous carcinoma, in which more 
than 95% of cases are laryngeal squamous cell carcinoma 
(LSCC) (1). This disease is a serious threat to patients' health 
and quality of life, especially for males, with a global inci-
dence rate of 5.1/100,000 in 2008 (2,3). Advanced laryngeal 
carcinoma usually indicates poor treatment efficacy and a 
higher recurrence rate. Patients with invasion and metastasis 
generally have a much worse prognosis and have a 5-year 
survival rate of ~60% (4). Therefore, more in-depth research 
of the molecular mechanisms may aid us in finding new diag-
nostic and/or therapeutic approaches to LSCC to improve the 
prognosis of LSCC patients (5).
Long non-coding RNAs (lncRNAs) usually range from 
200 nt to over 100 kb in length and are defined as endog-
enous cellular RNAs. At first, lncRNAs were discovered 
as ‘transcriptional noise’. Currently, lncRNAs are consid-
ered to be a primary element of the human transcriptome. 
However, there is little knowledge regarding most of these 
lncRNAs, which require functional explanation (6). More 
new evidence has shown that in tumorigenesis and in 
cancer progression, lncRNAs play an important regulatory 
role (7). More lncRNAs have been discovered and identified 
as oncogenic or anti-oncogenic in head and neck cancer, 
including TUG1 (8), HOTAIR (9), ANRIL (10), CCAT2 (11), 
MEG3 (12), LOC285194 (13) and 91H (14). However, little is 
known about the role of long non-coding RNA in predicting 
metastasis and patient prognosis of LSCC. Furthermore, 
the underlying mechanisms of lncRNA in regulating LSCC 
metastasis remain unclear.
Microarray analysis of LSCC tissues showed abnormal 
expression of the lncRNA RP11-169D4.1. It was demon-
strated that RP11-169D4.1 levels are significantly decreased 
in LSCC tissues, and decreased expression of RP11-169D4.1 
indicates a poor prognosis and increased lymph node metas-
tasis in patients with LSCC (15). However, the role of the 
lncRNA RP11-169D4.1 in LSCC remains unknown. In the 
present study, we further explored the role of the lncRNA 
RP11-169D4.1 and its potential underlying mechanism in 
LSCC.
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Materials and methods
Clinical specimens. A total of 51 patients with laryngeal 
squamous cell carcinoma were analyzed in the present study 
at the First Affiliated Hospital of Sun Yat-sen University 
(Guangzhou, China) between February 2012 and March 2014. 
All LSCC patients signed informed consent. The diagnosis of 
LSCC was histopathologically confirmed. Tumor and corre-
sponding adjacent normal tissues were selected from each 
patient. Normal human laryngeal tissues were obtained at a 
minimum of >10 mm from the edge of the cancerous area. 
Tissue samples were resected and immediately frozen in liquid 
nitrogen. They were stored at -80˚C until RNA extraction. The 
following clinicopathological data were collected: age, sex, 
tumor origin, TNM stage, lymph node metastasis, clinical 
stage and histological differentiation.
Cell culture. Human LSCC cell lines (SNU899 and SNU46) 
were obtained from Hong Kong University. All LSCC cells 
were maintained in Dulbecco's modified Eagle's medium 
(DMEM) with RPMI-1640, which was supplemented with 
10% fetal bovine serum (FBS). All LSCC cells were incubated 
in a humidified incubator with 5% CO2 at 37˚C.
RNA extraction. Total RNA was extracted using TRIzol® 
(Invitrogen, Carlsbad, CA, USA). A NanoDrop 1000 spectro-
photometer (Thermo Fisher Scientific, Waltham, MA, USA) 
was used to confirm the RNA quality. The criterion of accept-
able purity is an OD260/280 ratio of ~1.8. Reverse transcription 
was achieved with a First Strand cDNA Synthesis kit (Qiagen, 
Hilden, Germany) according to the manufacturer's protocol.
Transfection assays. The RP11-169D4.1 sequence (Gene: 
LINC01537, ENSG00000227467) was synthesized according 
to the full length RP11-169D4.1 sequence (based on the 
RP11-169D4.1 sequence) and then cloned into a pLvx vector 
(Invitrogen; Thermo Fisher Scientific). Then, either RP11-
169D4.1-pLvx or empty vector was transfected into LSCC 
cells using Lipofectamine 2000 reagent (Invitrogen; Thermo 
Fisher Scientific). The empty pLVX vector was used as the 
control.
Real-time quantitative RT-PCR. Real-time PCR was 
performed using the FastStart Universal Probe Master (Roche 
Applied Science, Indianapolis, IN, USA) on a LightCycler® 
480 (Roche Applied Science). Primers for real-time PCR were 
purchased from Integrated DNA Technologies (Coralville, IA, 
USA). The detection probe was obtained from Roche Applied 
Science. The reaction was incubated at 95˚C for 10 min 
followed by 55 cycles of 95˚C for 15 sec and 60˚C for 1 min. 
The mRNA was normalized to GAPDH levels using the 2-ΔΔCt 
method. The micro-RNA was normalized to U6 levels using 
the 2-ΔΔCt method.
Proliferation assay. LSCC cells (1x104) treated with either 
RP11-169D4.1-pLvx or empty vector were seeded into 96-well 
plates and cultured for 24, 48 and 72 h. Before the indicated 
time-point, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) (0.5 mg/ml, pH 4.7; Sigma-Aldrich, 
St. Louis, MO, USA) was added for 4 h. At the indicated times, 
the supernatant was removed and 150 µl of dimethyl sulfoxide 
(DMSO) was added to the plate before shaking for 15 min 
at room temperature. A microplate reader (Thermo Fisher 
Scientific) was used to measure the absorbance at 490 nm. 
The cell growth value was calculated from the mean values of 
6 identical wells.
Flow cytometric analysis. LSCC cells (2-5x105) treated with 
either RP11-169D4.1-pLvx or negative control (NC) were 
seeded into 6-well plates. The cells were harvested by trypsin-
ization after incubation for 48 h. The cells were double stained 
with Annexin v and 7-AAD (Nanjing KeyGen Biotech, Co., 
Ltd., Nanjing, China) in the dark for 30 min at 37˚C. The cells 
were collected and analyzed on a flow cytometer (FACScan; 
BD Biosciences, Franklin Lakes, NJ, USA) to determine the 
apoptosis levels.
Wound healing assay. Transfected cells (2-5x104/well) were 
cultured in 6-well plates and serum starved for 24 h, after 
which the medium was replaced with medium containing 
serum (10% FBS). A 100-µl pipette tip was used to scratch 
the cell monolayer, which was imaged at 0 and 24 h after the 
wounding.
Cell invasion assays. Cells (2x104/well) in 200 µl RPMI-1640 
were seeded into the upper chamber of a Transwell apparatus 
with Matrigel (BD Biosciences) after transfection for 24 h. 
The lower chambers were filled with media containing 15% 
FBS. The LSCC cells were incubated for 24 h. After the cells 
invaded the membrane, they were fixed with 95% ethanol for 
30 min. Cells on the lower surface were stained with 0.1% 
crystal violet, photographed in three independent fields and 
counted.
Western blot analysis. Total protein was isolated from LSCC 
cells. A BCA protein quantification kit was used to determine 
the protein concentration. Proteins were separated on a 10% 
sodium dodecyl sulfate-polyacrylamide gel using SDS-PAGE 
and transferred electrophoretically onto polyvinylidene 
difluoride membranes (Whatman, Maidstone, UK). Then, 
the membranes were blocked for 1 h in 5% skim milk and 
washed three times with Tris-buffered saline containing 20% 
Tween-20 (TBST) at room temperature. The membranes 
were incubated with the primary antibodies overnight at 4˚C, 
washed the following day with TBST and incubated with 
secondary antibody for 1 h at room temperature. Finally, the 
immunoreactivity was visualized by enhanced chemilumines-
cence.
Mouse monoclonal anti-GAPDH (cat. no. KM9002; 
1:5,000; Tianjin Sungene Biotech, Co., Ltd,. Tianjin, China), 
rabbit monoclonal anti-vimentin (cat. no. 5741S; 1:1,000; Cell 
Signaling Technology, Danvers, MA, USA), rabbit mono-
clonal E-cadherin (cat. no. A0965; 1:1,000; ABclonad, Inc., 
Seoul, Korea), rabbit monoclonal SNAIL2 (cat. no. A0572; 
1:500; ABclonad), rabbit monoclonal AKT (cat. no. 4691S; 
1:1,000; Cell Signaling Technology) and rabbit monoclonal 
p-AKT (cat. no. 4060S; 1:2,000; Cell Signaling Technology) 
primary antibodies were used. Goat anti-mouse IgG-HRP (cat. 
no. BA1050; 1:5,000; Wuhan Boster Bio-engineering, Co., 
Ltd., Wuhan, China) and goat anti-rabbit IgG-HRP (cat. no. 
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BA1055; 1:5,000; Wuhan Boster Bio-engineering) were used 
as secondary antibodies.
Argonaute 2 (AGO2) protein immunoprecipitation. LSCC 
cells were transfected with either miR-205-5p inhibitor or 
negative control (Qiagen) using the Lipofectamine 2000 
reagent. Subsequently, a human Argonaute 2 (Ago2) miRNA 
isolation kit (Wako Pure Chemical Industries, Osaka, Japan) 
was used to isolate the Ago2 complex. After transfection, the 
cells were lysed, and anti-Ago2 monoclonal antibody-immobi-
lized beads (Wako Pure Chemical Industries) were added to 
the cell lysate. After incubation for 2 h at 4˚C, the beads were 
washed with wash buffer, and the Ago2 complex was eluted 
from the beads. The levels of miR-205-5p and RP11-169D4.1 
were measured from the eluted Ago2 complex. The PCR 
primer-probe pairs for RP11-169D4.1 quantification were as 
follows: forward primer, 5'-CCGGAATTCCCCAGACACAG 
GGCAGCCTTCC-3' and reverse primer, 5'-ATAAGAATG 
CGGCCGCTTTTATATAATATTTTGAAT-3'; probe, #15 
from the Universal Probe Library (Roche Applied Science). 
The PCR primer-probe pair for miR-205-5p quantification was 
Figure 1. Analysis of RP11-169D4.1 expression in LCSS tissues and LSCC 
cell lines. (A) Relative expression of RP11-169D4.1 in LSCC tissues (n=51) 
compared with adjacent normal tissues. RP11-169D4.1 expression was 
examined by RT-qPCR and normalized to GAPDH. (B) RP11-169D4.1 
expression levels were determined by RT-qPCR in LSCC cell lines (SNU899 
and SNU46) and the normal throat epithelial cell line (HOK). **P<0.01. 
(C and D) SNU899 and SNU46 cells were transfected with empty vector 
or RP11-169D4.1-pLvx for 48 h, and the expression of RP11-169D4.1 was 
measured by qRT-PCR.
Table I. Relationship between RP11-169D4.1 expression and 
tumor clinicopathological features in LSCC.
 RP11-169D4.1
 expression ------------------------
  Low High
variables Cases (26) (25) P-valuea
Sex
  Male 50 25 25 0.322
  Female 1 1 0
Age (years)
  <60 29 11 18 0.032a
  ≥60 22 15 7
T stage
  T1-2 20 8 12 0.208
  T3-4 31 18 13
Lymph node
  Positive 20 14 6 0.029a
  Negative 31 12 19
Clinical stage
  Early 16 6 10 0.193
  Advance 35 20 15
Histological differentiation
  Well and moderately 29 13 16 0.313
  differentiated
  Poor and undifferentiated 22 13 9
CDH1 expression
  Low  26 17 9 0.036a
  High 25 9 16
The correlation between RP11-169D4.1 and CDH1
Pearson correlation 0.744
P-value <0.001b
CDH1, cadherin 1; aP<0.05; bP<0.01.
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as follows: 5'-TCCTTCATTCCACCGGAGTCTG-3'; probe 
#61. The expression level of glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was quantified using the Universal Probe 
Library Human GAPD Gene Assay (Roche Applied Science).
Statistical analysis. Data were reported as the means ± stan-
dard deviation from at least three independent experiments. All 
of the statistical analyses were performed using the SPSS 20.0 
statistical software (IBM, New York, NY, USA) with either 
Student's t-test (two tailed) or one-way analysis of variance 
(ANOvA) for multiple groups. Differences were considered 
statically significant at the probability of P<0.05.
Results
RP11-169D4.1 expression is downregulated in LSCC tissues 
and cell lines. The expression levels of lncRNA RP11-
169D4.1 were evaluated by qRT-PCR in 51 paired LSCC 
tissues and adjacent normal tissues. As shown in Fig. 1A, 
RP11-169D4.1 expression was much lower in LSCC tissues 
than that in normal tissues (P<0.001). The clinicopathological 
characteristics of the 51 patients, including age, sex, tumor 
origin, TNM stage, lymph node metastasis, clinical stage and 
histological differentiation are presented in Table I. LncRNA 
RP11-169D4.1 expression in cancer tissues was associated 
with lymph node metastasis (P=0.029). The expression of 
RP11-169D4.1 was significantly downregulated in LSCC cell 
lines compared with normal throat epithelial cells as shown 
in Fig. 1B.
RP11-169D4.1 suppresses proliferation and promotes apop-
tosis in LSCC cells. To investigate the role of RP11-169D4.1 
in the regulation of cell proliferation and apoptosis, SNU899 
and SNU46 cells were transfected with RP11-169D4.1-pLvx. 
qRT-PCR was used to measure the expression of RP11-169D4.1, 
which was greatly increased (Fig. 1C and D).
The growth curves determined by the MTT assay showed 
that overexpression of RP11-169D4.1 could suppress the 
Figure 2. RP11-169D4.1 suppresses LSCC cell proliferation and promotes apoptosis. Overexpression of RP11-169D4.1 decreased the (A-D) SNU899 and 
SNU46 cells growth. *P<0.05, **P<0.01. At 48 h after transfection, cell apoptosis was analyzed by flow cytometry. Late apoptotic cells increased significantly 
after 48 h transfection with RP11-169D4.1-pLvx compared to controls in (E and F) SNU899 and (G and H) SNU46 cells.
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proliferation of SNU899 and SNU46 cells at 24, 48 and 72 h 
after transfection (Fig. 2A-D). The apoptosis assay showed that 
the percentage of apoptotic cells was significantly increased 
in response to RP11-169D4.1 overexpression compared with 
NC overexpression in SNU899 and SNU46 cells (Fig. 2E-H). 
These results indicated the anti-proliferative and pro-apoptotic 
role of RP11-169D4.1 in LSCC cells.
RP11-169D4.1 inhibits migration and invasion in LSCC cells. 
To examine the effect of RP11-169D4.1 on migration and inva-
sion of LSCC cells, wound healing and Transwell invasion 
assays were conducted. We found that LSCC cells transfected 
with RP11-169D4.1-pLvx showed less wound closure than 
cells transfected with empty pLvx vector (Fig. 3A and B). The 
Transwell assays showed that overexpression of RP11-169D4.1 
inhibited the invasion of LSCC cells transfected with 
RP11-169D4.1-pLvx (Fig. 3C-F). These results suggest that 
RP11-169D4.1 contributes to the inhibition of the migratory 
and invasive capacity of LSCC cells.
RP11-169D4.1 inhibits EMT in LSCC cells. To determine 
whether overexpression of RP11-169D4.1 inhibits epithelial-
mesenchymal transitions (EMT) in LSCC cells, we enhanced 
RP11-169D4.1 expression in SNU899 and SNU46 cells and 
examined the mRNA expression of EMT markers by RT-PCR 
and the protein levels by western blot assay. As illustrated in 
Fig. 4, the level of CDH1 was improved, and the levels of Snail2 
and vimentin were reduced in cells transfected with RP11-
169D4.1-pLvx. These results showed that RP11-169D4.1 was 
able to inhibit EMT in LSCC cells.
RP11-169D4.1 was targeted and inhibited by miR-205-5p. 
Given the observation that RP11-169D4.1 played an important 
role in regulating the biological properties of LSCC cells, we 
next investigated the potential mechanisms of RP11-169D4.1 
using the bioinformatics tool RNA22 (16). RNA22 predicted 
that RP11-169D4.1 was a target of miR-205-5p (Fig. 5A). We 
transfected LSCC cells with either a miR-205-5p inhibitor 
or miR-NC and confirmed the transfection efficiency using 
Figure 3. RP11-169D4.1 suppresses LSCC cell migration and invasion. Wound healing assay shows that SNU899 (A) and SNU46 (B) cell motility could 
be effectively suppressed by RP11-169D4.1-pLvx compared by empty vector. Upregulation of RP11-169D4.1 in SNU899 (C and D) and SNU46 (E and F) 
significantly inhibited invasion compared with the control group. *P<0.05, **P<0.01.
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RT-PCR. SNU899 and SNU46 cells with low expression of 
miR-205-5p showed higher levels of RP11-169D4.1 compared 
with the negative control cells (Fig. 5D). However, the over-
expression of RP11-169D4.1 did not affect the expression of 
miR-205-5p in LSCC cells (Fig. 5E), which indicates that 
miR-205-5p might inhibit the expression of RP11-169D4.1.
We performed immunoprecipitation of endogenous 
protein-mRNA complexes in SNU899 and SNU46 cells. Both 
miR-205-5p and RP11-169D4.1 were enriched in the immuno-
purified AGO2 complex, suggesting that RP11-169D4.1 is an 
AGO2-selected transcript in the LSCC cell lines. In the cell 
lines transfected with the miR-205-5p inhibitor, the transcript 
level of mature miR-205-5p and RP11-169D4.1 dropped signif-
icantly compared with the cell lines transfected with miR-NC 
(Fig. 5B and C). The results indicated that mature miR-205-5p 
could possibly bind to the RP11-169D4.1 transcript and hinder 
RP11-169D4.1 expression by 3'-UTR-mediated mRNA degra-
dation.
CDH1 expression is downregulated and correlated with RP11-
169D4.1 in LSCC tissues. CDH1, also known as E-cadherin, 
is a well-established tumor suppressor (17-19). Loss of CDH1 
can trigger EMT and also has a strong association with the 
invasive metastasis of various tumors (20,21). By using the 
Oncomine StarBase, large sets of data that show reduced 
CDH1 mRNA levels in various cancerous tissues compared 
to normal tissues can be searched (Fig. 6). To determine the 
correlation between RP11-169D4.1 and CDH1, we further 
analyzed the expression of CDH1 in 51 paired LSCC tissues 
and adjacent normal tissues. CDH1 was identified as having 
lower expression in LSCC tissues than in normal tissues 
(P=0.038; Fig. 7A). In addition, the correlation analysis 
revealed that there was a positive correlation between the 
expression of RP11-169D4.1 and CDH1 (P<0.001; R2=0.744) 
(Table I; Fig. 7B).
As shown in Fig. 4, the upregulation of RP11-169D4.1 
could enhance the level of CDH1 protein. Furthermore, we 
found that the expression of CDH1 mRNA was significantly 
improved in the cells transfected with RP11-169D4.1-pLvx 
compared to cells transfected with empty vector. These results 
indicated that RP11-169D4.1 could modulate the expression 
of CDH1.
Figure 4. qRT-PCR analysis of CDH1 (A and B), Snail2 and vimentin (C and D) mRNA levels in SNU899 and SNU46 cells following RP11-169D4.1 overex-
pression. (E and F) Western blot analysis of CDH1, Snail2 and vimentin protein levels in SNU899 and SNU46 cells following RP11-169D4.1 overexpression. 
*P<0.05, **P<0.01.
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RP11-169D4.1 exerts its function via the AKT signaling 
pathway. According to studies that showed that loss of CDH1 
could activate AKT signaling, we proposed that RP11-169D4.1 
could regulate the AKT signaling pathway through CDH1. We 
detected the levels of AKT and phospho-AKT in LSCC cell 
lines. As expected, the level of p-AKT was reduced after cells 
were transfected with RP11-169D4.1-pLvx and total AKT 
levels were constant (Fig. 7C and D). These results suggest that 
RP11-169D4.1 may be a major player in the AKT signaling 
pathway.
Discussion
With the fast development of human genome and transcrip-
tome sequencing technologies, much attention has been 
focused on lncRNA. lncRNAs could serve as potential diag-
nostic biomarkers and effective therapeutic targets. In the near 
future, in-depth research of lncRNAs is an attractive avenue to 
discover novel biomarkers or targets (22). To date, many studies 
have explored the various functions of lncRNAs in head and 
neck neoplasms (23). For example, the overexpression of UCA1 
could promote the metastasis of TSCC cells (24). HOTAIR 
participated in PTEN methylation in Hep-2 cells (25) and had 
close correlation with miR-21 in LSCC (26). MALAT1 was a 
novel target of miR-217 and miR-101 and could stimulate the 
invasion and metastasis of ESCC cells (27).
It was observed that RP11-169D4.1 expression was down-
regulated in LSCC tissues and metastatic neck lymph nodes, 
and lower expression of RP11-169D4.1 predicted poor prog-
nosis. In another study, the downregulation of RP11-169D4.1 
in LSCC tissues was also observed (28). However, these studies 
were limited to its abnormal expression in LSCC. However, 
the specific function of RP11-169D4.1 and its potential mecha-
nisms in LSCC still remain unknown.
In the present study, we first clarified the function of 
RP11-169D4.1, which was thought to play a tumor-suppres-
sive role in LSCC. Moreover, RP11-169D4.1 expression was 
significantly correlated with LSCC metastasis to the neck 
Figure 5. (A) Alignment of potential miR-205-5p base pairing with RP11-169D4.1 as identified by RNA22 program (https://cm.jefferson.edu/rna22/). 
(B and C) Relative expression level of miR-205-5p and RP11-169D4.1 mRNA in AGO2 complex from stable laryngeal carcinoma clone compromising 
miR-NC or miR-205-5p inhibitor. (D) With miR-205-5p suppression, RP11-169D4.1 mRNA level was remarkably increased. (E) With RP11-169D4.1 overex-
pression, the change of miR-205-5p mRNA level was not statistically significant. *P<0.05, **P<0.01.
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lymph nodes. These data suggested that RP11-169D4.1 
might participate in the metastasis of LSCC. The molecular 
mechanisms that control the expression of RP11-169D4.1 
are now being elucidated. Through the bioinformatics tool 
RNA22, we know that RP11-169D4.1 might be a target of 
miR-205-5p. As an oncogenic microRNA, miR-205-5p has 
been well characterized for its role in LSCC (29). Some 
studies have indicated that miR-205-5p promotes the 
proliferation, migration and invasion of LSCC (30). Our 
findings highlight the interaction between miR-205-5p and 
the lncRNA RP11-169D4.1 during tumorigenesis and the 
progression of LSCC cells.
Next, we explored the molecular mechanisms underlying 
RP11-169D4.1 inhibition of EMT. EMT has been identi-
fied as a paramount event in the early periods of metastatic 
dissemination in various tumor cells. During these periods, 
tumor cells become more active and have a stronger invasive 
ability (31). The CDH1 gene encodes E-cadherin, which is a 
transmembrane glycoprotein and a prototypical member of the 
classical cadherin family. E-cadherin/CDH1 plays a critical 
role in preserving cell polarity as well as maintaining epithelial 
integrity. It was reported that CDH1 expression was correlated 
with the metastasis to neck lymph nodes and the TNM stages 
in LSCC (32). As CDH1 is the most commonly expressed gene 
during EMT, we investigated whether RP11-169D4.1 could 
regulate the expression of CDH1.
To further explore the mechanisms of RP11-169D4.1, we 
tried to find the potential signaling pathway of RP11-169D4.1. 
Figure 6. Box and whisker plots of Oncomine data on CDH1 mRNA levels (expressed as the log2 median-centered ratio) in various normal and cancerous 
tissues. P-values, Student's t-test.
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Previous studies have shown that CDH1 expression is regulated 
through the AKT pathway (33), and miR-205-5p promotes 
tumor metastasis by activating the AKT signaling (34), which 
indicates that RP11-169D4.1 might regulate the AKT signaling 
pathway by modulating CDH1. The AKT pathway is consid-
ered to be closely related to laryngeal carcinoma (35,36). These 
results suggest that the miR-205-5p/RP11-169D4.1/CDH1/AKT 
signaling pathway may play an important role in the develop-
ment of LSCC.
EMT is a process that results in the migration, invasion 
and metastasis of cancer cells. At the same time, loss of 
CDH1 (E-cadherin) is considered as a fundamental event 
in EMT. Several studies indicate that patients with lymph 
node metastasis tend to have higher recurrence rate and poor 
prognosis and RP11-169D4.1 can be considered as a predictor 
of lymph node metastasis in patients. However, the specific 
mechanism of regulating CDH1 for RP11-169D4.1 still needs 
further exploration. Continued study of these molecules and 
an improved understanding of the lncRNA RP11-169D4.1 will 
facilitate the development of more effective therapies against 
human laryngeal carcinoma.
In conclusion, the lncRNA RP11-169D4.1 is down-
regulated in LSCC and is associated with lymph node 
metastasis. Overexpression of RP11-169D4.1 in LSCC 
cells decreased cell migration and invasion in vitro. miR-
205-5p acted as the upstream molecule of RP11-169D4.1 
activity. Furthermore, RP11-169D4.1 could suppress the 
process of EMT by modulating CDH1 expression. The 
miR-205-5p/RP11-169D4.1/CDH1/AKT signaling pathway is 
an important part of the molecular mechanisms of EMT in 
LSCC. RP11-169D4.1 may be a novel and valuable therapeutic 
target in predicting outcomes of patients with LSCC.
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